4XB.F XBiotech Inc

Healthcare Biotechnology Frankfurt Exchange
1.72 EUR
Close of Nov 11, 2026
1.51 2.18
Market cap
EUR 52.4M
P/E
-
P/B
0.45x
ROE
-19.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 4XB.F undervalued?

Graham number

The Graham number of XBiotech Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

XBiotech Inc fundamental analysis

No fundamental analysis for XBiotech Inc yet.

XBiotech Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About XBiotech Inc

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and gener…

Full company profile